查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1472053

成纖維細胞生長因子的全球市場 - 全球產業分析、規模、份額、成長、趨勢、預測 (2024-2031) - 按產品、按應用、按最終用戶、按地區、按公司

Fibroblast Growth Factors Market - Global Fibroblast Growth Factors Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2031 - (By Product Coverage, By Application Coverage, By End User Coverage, By Geographic Coverage and By Company)
出版日期: | 出版商: Fairfield Market Research | 英文 185 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

全球纖維母細胞生長因子 (FGF) 市場規模預計將從 2024 年的約 2.8 億美元大幅擴張至 2031 年的 5 億美元，我正在努力實現顯著的快速成長。 預計 2024 年至 2031 年期間，該市場將以 8.64% 的複合年增長率擴張。

從 2024 年到 2031 年，在各種治療應用的需求和採用不斷增加的推動下，市場收入預計將增長 1.7 倍以上。

FGF已應用於傷口癒合、組織再生、腫瘤學、皮膚病學、心血管疾病和神經系統疾病等多個領域，並在多個領域展現出快速增長的治療潛力。

FGF 市場的擴張受到多種因素的推動，包括醫療保健支出的增加、生物技術的技術進步以及跨治療領域的應用擴展，這表明了強勁的成長軌跡。

本報告調查了全球纖維母細胞生長因子市場，並提供了市場概述，以及進入市場的公司的產品、應用、最終用戶、區域和競爭趨勢的趨勢。

目錄

第 1 章執行摘要

第2章市場概述

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影響分析
  • 烏克蘭與俄羅斯衝突的影響
  • 經濟概況
  • 杵分析

第3章2019-2031 年全球纖維母細胞生長因子市場展望

  • 2019-2031 年全球纖維母細胞生長因子市場展望（按產品、價值（十億美元））
  • 2019-2031 年全球纖維母細胞生長因子市場展望（按應用、價值（十億美元））
  • 全球纖維母細胞生長因子市場前景（按最終用戶劃分），價值（十億美元），2019-2031 年
  • 2019-2031 年全球纖維母細胞生長因子市場前景（按地區、價值（十億美元））

第 4 章北美纖維母細胞生長因子市場展望，2019-2031

第5章歐洲纖維母細胞生長因子市場展望，2019-2031

第 6 章亞太地區纖維母細胞生長因子市場展望，2019-2031

第 7 章拉丁美洲纖維母細胞生長因子市場展望，2019-2031

第 8 章中東與非洲纖維母細胞生長因子市場展望，2019-2031

第9章競爭態勢

  • 以最終使用者和使用情況劃分的熱圖
  • 2023 年公司市佔率分析
  • 競爭對手儀表板
  • 公司簡介
    • Thermo Fisher Scientific
    • Sigma-Aldrich (now part of Merck KGaA)
    • PeproTech
    • R&D Systems (a Bio-Techne brand)
    • Abcam
    • Cell Signaling Technology
    • Novus Biologicals

第10章 附錄

簡介目錄

Global fibroblast growth factors (FGF) market is poised to experience a substantial surge, with projections indicating a remarkable expansion to US$500 million by 2031 from approximately US$280 million in 2024. This forecast reflects an impressive compound annual growth rate (CAGR) of 8.64% during the period spanning 2024 to 2031.

Significant Revenue Surge:

The market anticipates more than a 1.7x expansion in revenue between 2024 and 2031, propelled by increasing demand and adoption across various therapeutic applications.

Diverse Applications:

FGFs find applications in diverse fields such as wound healing, tissue regeneration, oncology, dermatology, cardiovascular diseases, and neurological disorders, showcasing burgeoning therapeutic potential across multiple sectors.

Growth Drivers:

Expansion in the FGF market is driven by several factors including increased healthcare expenditure, technological advancements in biotechnology, and widening applications across therapeutic areas, indicating a robust trajectory for growth.

Challenges:

Despite the promising outlook, the market faces challenges such as regulatory hurdles, safety concerns regarding adverse effects, and limited commercialization infrastructure, which require strategic solutions and collaborative efforts from industry stakeholders.

Industry Trends:

Notable trends shaping the FGF market include the rise of personalized medicine in oncology, collaborative research initiatives among industry players, and the exploration of expanded therapeutic applications beyond traditional indications.

Opportunities:

Exploring novel therapeutic applications and expanding into emerging markets, particularly in the Asia Pacific region, present significant growth opportunities for players in the FGF market.

Regional Insights:

North America leads the market, followed by Europe and the Asia Pacific, with the Rest of the World showing potential for growth, driven by evolving healthcare infrastructure and increasing adoption of advanced medical technologies.

Key Players:

Major industry players such as Amgen, Pfizer, and Johnson & Johnson dominate the market landscape, leveraging continuous research and development efforts, strategic partnerships, and innovative product development to maintain their competitive edge.

Notable Developments:

Recent noteworthy developments in the FGF market include Amgen's RegenFibra(TM) for diabetic foot ulcers, Pfizer's RejuvaGlow(TM) dermal filler, and Johnson & Johnson's orthopaedic implants distribution agreement, reflecting ongoing innovation and investment in the sector.

Key Growth Determinants:

Expansion of FGF applications across various therapeutic areas, continuous technological advancements in biotechnology, and the increasing healthcare expenditure Globally are key determinants fueling market growth.

Major Growth Barriers:

Stringent regulatory requirements, safety concerns related to adverse effects, and limited commercialization infrastructure pose significant barriers to the growth of the FGF market, necessitating proactive measures and collaborative efforts to address these challenges.

Key Trends and Opportunities to Look at:

Key trends such as the personalized medicine boom in oncology, collaborative research initiatives, and the exploration of expanded therapeutic applications present exciting opportunities for industry players to capitalize on.

Regional Frontrunners:

North America leads the Global FGF market, benefitting from established regulatory frameworks and high healthcare expenditure, followed by Europe and the Asia Pacific, which hold immense promise due to factors such as government funding for innovation and a rapidly aging population.

Fairfield's Competitive Landscape Analysis:

The FGF market is fiercely competitive, with industry leaders such as Thermo Fisher Scientific, Merck KGaA (formerly Sigma-Aldrich), PeproTech, and others dominating the landscape. Key growth strategies include product development, strategic partnerships, and market expansion initiatives.

Leaders in Global Fibroblast Growth Factors Space:

Leading companies in the Global FGF market include Thermo Fisher Scientific, Merck KGaA (formerly Sigma-Aldrich), PeproTech, R&D Systems (a Bio-Techne brand), Abcam, Cell Signaling Technology, and Novus Biologicals, among others.

Global Fibroblast Growth Factors Market Segmentation:

By Product:

FGF1

FGF2

FGF3

FGF4

FGF7

FGF10

FGF11

FGF12

FGF13

FGF14

FGF15

FGF18

FGF19

FGF20

FGF23

By Application:

Oncology

Hematology

Wound Healing

Dermatology

Cardiovascular Disease & Diabetes

Cell Culture

By End User:

Pharmaceutical and Biotechnology Companies

Research Centers & Academic Institutes

Contract Manufacturing Organizations (CMO) and Contract Development and Manufacturing Organizations (CDMO)

By Region:

North America

Latin America

Europe

East Asia

South Asia

Oceania

Middle East and Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Fibroblast Growth Factors Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Fibroblast Growth Factors Market Outlook, 2019 - 2031

  • 3.1. Global Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. FGF1
      • 3.1.1.2. FGF2
      • 3.1.1.3. FGF3
      • 3.1.1.4. FGF4
      • 3.1.1.5. FGF7
      • 3.1.1.6. FGF10
      • 3.1.1.7. FGF11
      • 3.1.1.8. FGF12
      • 3.1.1.9. FGF13
      • 3.1.1.10. FGF14
      • 3.1.1.11. FGF15
      • 3.1.1.12. FGF18
      • 3.1.1.13. FGF19
      • 3.1.1.14. FGF20
      • 3.1.1.15. FGF23
      • 3.1.1.16. Others
  • 3.2. Global Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Oncology
      • 3.2.1.2. Hematology
      • 3.2.1.3. Wound Healing
      • 3.2.1.4. Dermatology
      • 3.2.1.5. Cardiovascular Disease & Diabetes
      • 3.2.1.6. Cell Culture
      • 3.2.1.7. Others
  • 3.3. Global Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Pharmaceutical & Biotechnology Companies
      • 3.3.1.2. Research Centers & Academic Institutes
      • 3.3.1.3. CMOs & CDMOs
  • 3.4. Global Fibroblast Growth Factors Market Outlook, by Region, Value (US$ Bn), 2019 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Fibroblast Growth Factors Market Outlook, 2019 - 2031

  • 4.1. North America Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. FGF1
      • 4.1.1.2. FGF2
      • 4.1.1.3. FGF3
      • 4.1.1.4. FGF4
      • 4.1.1.5. FGF7
      • 4.1.1.6. FGF10
      • 4.1.1.7. FGF11
      • 4.1.1.8. FGF12
      • 4.1.1.9. FGF13
      • 4.1.1.10. FGF14
      • 4.1.1.11. FGF15
      • 4.1.1.12. FGF18
      • 4.1.1.13. FGF19
      • 4.1.1.14. FGF20
      • 4.1.1.15. FGF23
      • 4.1.1.16. Others
  • 4.2. North America Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Oncology
      • 4.2.1.2. Hematology
      • 4.2.1.3. Wound Healing
      • 4.2.1.4. Dermatology
      • 4.2.1.5. Cardiovascular Disease & Diabetes
      • 4.2.1.6. Cell Culture
      • 4.2.1.7. Others
  • 4.3. North America Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Pharmaceutical & Biotechnology Companies
      • 4.3.1.2. Research Centers & Academic Institutes
      • 4.3.1.3. CMOs & CDMOs
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 4.4.1.2. U.S. Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 4.4.1.3. U.S. Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 4.4.1.4. Canada Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 4.4.1.5. Canada Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 4.4.1.6. Canada Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Fibroblast Growth Factors Market Outlook, 2019 - 2031

  • 5.1. Europe Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. FGF1
      • 5.1.1.2. FGF2
      • 5.1.1.3. FGF3
      • 5.1.1.4. FGF4
      • 5.1.1.5. FGF7
      • 5.1.1.6. FGF10
      • 5.1.1.7. FGF11
      • 5.1.1.8. FGF12
      • 5.1.1.9. FGF13
      • 5.1.1.10. FGF14
      • 5.1.1.11. FGF15
      • 5.1.1.12. FGF18
      • 5.1.1.13. FGF19
      • 5.1.1.14. FGF20
      • 5.1.1.15. FGF23
      • 5.1.1.16. Others
  • 5.2. Europe Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Oncology
      • 5.2.1.2. Hematology
      • 5.2.1.3. Wound Healing
      • 5.2.1.4. Dermatology
      • 5.2.1.5. Cardiovascular Disease & Diabetes
      • 5.2.1.6. Cell Culture
      • 5.2.1.7. Others
  • 5.3. Europe Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Pharmaceutical & Biotechnology Companies
      • 5.3.1.2. Research Centers & Academic Institutes
      • 5.3.1.3. CMOs & CDMOs
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 5.4.1.2. Germany Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 5.4.1.3. Germany Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 5.4.1.4. U.K. Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 5.4.1.5. U.K. Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 5.4.1.6. U.K. Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 5.4.1.7. France Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 5.4.1.8. France Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 5.4.1.9. France Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 5.4.1.10. Italy Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 5.4.1.11. Italy Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 5.4.1.12. Italy Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 5.4.1.13. Turkey Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 5.4.1.14. Turkey Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 5.4.1.15. Turkey Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 5.4.1.16. Russia Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 5.4.1.17. Russia Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 5.4.1.18. Russia Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 5.4.1.19. Rest of Europe Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 5.4.1.20. Rest of Europe Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 5.4.1.21. Rest of Europe Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Fibroblast Growth Factors Market Outlook, 2019 - 2031

  • 6.1. Asia Pacific Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. FGF1
      • 6.1.1.2. FGF2
      • 6.1.1.3. FGF3
      • 6.1.1.4. FGF4
      • 6.1.1.5. FGF7
      • 6.1.1.6. FGF10
      • 6.1.1.7. FGF11
      • 6.1.1.8. FGF12
      • 6.1.1.9. FGF13
      • 6.1.1.10. FGF14
      • 6.1.1.11. FGF15
      • 6.1.1.12. FGF18
      • 6.1.1.13. FGF19
      • 6.1.1.14. FGF20
      • 6.1.1.15. FGF23
      • 6.1.1.16. Others
  • 6.2. Asia Pacific Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Oncology
      • 6.2.1.2. Hematology
      • 6.2.1.3. Wound Healing
      • 6.2.1.4. Dermatology
      • 6.2.1.5. Cardiovascular Disease & Diabetes
      • 6.2.1.6. Cell Culture
      • 6.2.1.7. Others
  • 6.3. Asia Pacific Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Pharmaceutical & Biotechnology Companies
      • 6.3.1.2. Research Centers & Academic Institutes
      • 6.3.1.3. CMOs & CDMOs
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 6.4.1.2. China Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 6.4.1.3. China Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 6.4.1.4. Japan Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 6.4.1.5. Japan Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 6.4.1.6. Japan Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 6.4.1.7. South Korea Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 6.4.1.8. South Korea Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 6.4.1.9. South Korea Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 6.4.1.10. India Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 6.4.1.11. India Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 6.4.1.12. India Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 6.4.1.13. Southeast Asia Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 6.4.1.14. Southeast Asia Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 6.4.1.15. Southeast Asia Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 6.4.1.16. Rest of Asia Pacific Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 6.4.1.17. Rest of Asia Pacific Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 6.4.1.18. Rest of Asia Pacific Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Fibroblast Growth Factors Market Outlook, 2019 - 2031

  • 7.1. Latin America Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. FGF1
      • 7.1.1.2. FGF2
      • 7.1.1.3. FGF3
      • 7.1.1.4. FGF4
      • 7.1.1.5. FGF7
      • 7.1.1.6. FGF10
      • 7.1.1.7. FGF11
      • 7.1.1.8. FGF12
      • 7.1.1.9. FGF13
      • 7.1.1.10. FGF14
      • 7.1.1.11. FGF15
      • 7.1.1.12. FGF18
      • 7.1.1.13. FGF19
      • 7.1.1.14. FGF20
      • 7.1.1.15. FGF23
      • 7.1.1.16. Others
  • 7.2. Latin America Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Oncology
      • 7.2.1.2. Hematology
      • 7.2.1.3. Wound Healing
      • 7.2.1.4. Dermatology
      • 7.2.1.5. Cardiovascular Disease & Diabetes
      • 7.2.1.6. Cell Culture
      • 7.2.1.7. Others
  • 7.3. Latin America Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Pharmaceutical & Biotechnology Companies
      • 7.3.1.2. Research Centers & Academic Institutes
      • 7.3.1.3. CMOs & CDMOs
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 7.4.1.2. Brazil Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 7.4.1.3. Brazil Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 7.4.1.4. Mexico Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 7.4.1.5. Mexico Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 7.4.1.6. Mexico Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 7.4.1.7. Argentina Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 7.4.1.8. Argentina Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 7.4.1.9. Argentina Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 7.4.1.10. Rest of Latin America Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 7.4.1.11. Rest of Latin America Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 7.4.1.12. Rest of Latin America Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Fibroblast Growth Factors Market Outlook, 2019 - 2031

  • 8.1. Middle East & Africa Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. FGF1
      • 8.1.1.2. FGF2
      • 8.1.1.3. FGF3
      • 8.1.1.4. FGF4
      • 8.1.1.5. FGF7
      • 8.1.1.6. FGF10
      • 8.1.1.7. FGF11
      • 8.1.1.8. FGF12
      • 8.1.1.9. FGF13
      • 8.1.1.10. FGF14
      • 8.1.1.11. FGF15
      • 8.1.1.12. FGF18
      • 8.1.1.13. FGF19
      • 8.1.1.14. FGF20
      • 8.1.1.15. FGF23
      • 8.1.1.16. Others
  • 8.2. Middle East & Africa Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Oncology
      • 8.2.1.2. Hematology
      • 8.2.1.3. Wound Healing
      • 8.2.1.4. Dermatology
      • 8.2.1.5. Cardiovascular Disease & Diabetes
      • 8.2.1.6. Cell Culture
      • 8.2.1.7. Others
  • 8.3. Middle East & Africa Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Pharmaceutical & Biotechnology Companies
      • 8.3.1.2. Research Centers & Academic Institutes
      • 8.3.1.3. CMOs & CDMOs
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Fibroblast Growth Factors Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 8.4.1.2. GCC Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 8.4.1.3. GCC Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 8.4.1.4. South Africa Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 8.4.1.5. South Africa Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 8.4.1.6. South Africa Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 8.4.1.7. Egypt Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 8.4.1.8. Egypt Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 8.4.1.9. Egypt Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 8.4.1.10. Nigeria Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 8.4.1.11. Nigeria Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 8.4.1.12. Nigeria Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Fibroblast Growth Factors Market by Product, Value (US$ Bn), 2019 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Fibroblast Growth Factors Market by Application, Value (US$ Bn), 2019 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Fibroblast Growth Factors Market by End User, Value (US$ Bn), 2019 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By End User vs by Application Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Thermo Fisher Scientific
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Sigma-Aldrich (now part of Merck KGaA)
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. PeproTech
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. R&D Systems (a Bio-Techne brand)
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Abcam
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Cell Signaling Technology
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Novus Biologicals
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations